Oncogenetic testing portfolio (germline mutations)

In April 2015, Centogene broadened its Oncogenetics portfolio by introducing both targeted and comprehensive screening for hereditary cancers. Targeted panels screen for germline mutations in genes that determine an inherited predisposition to, or increased risk for, certain cancers such as: Breast, Ovarian, Colon, Gastric, Pancreatic, Renal, Skin, Thyroid, Uterine as well as Paragangliomas (PGLs), Pheochromocytomas (PCCs) and Gastro-Intestinal Stromal Tumors (GIST). These specific targeted panels are tailored to screen affected patients or probands who have a family history of a particular kind of cancer. However, in addition, we offer the Comprehensive panel in order to screen for a wide spectrum of inherited cancers in persons or families with no clear differential diagnoses regarding a specific heritable tumor syndrome.